Boxer Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Boxer Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,430,004	Closed	-$146M	–	82
2023 Q2	$146M	Buy	1,430,004 +200,000	+16%	+$18.9M	6.76%	1
2023 Q1	$112M	Hold	1,230,004	–	–	5.49%	2
2022 Q4	$46.7M	Sell	1,230,004 -8,996	-0.7%	-$310K	2.46%	11
2022 Q3	$31.1M	Hold	1,239,000	–	–	1.75%	20
2022 Q2	$37.7M	Hold	1,239,000	–	–	2.38%	15
2022 Q1	$40.6M	Buy	+1,239,000	New	+$36.8M	2.09%	16
2019 Q1	–	Sell	-50,000	Closed	-$2.81M	–	27
2018 Q4	$2.81M	Sell	50,000 -350,000	-88%	-$21.4M	0.35%	23
2018 Q3	$32.7M	Buy	400,000 +75,000	+23%	+$5.29M	3.63%	11
2018 Q2	$11.4M	Hold	325,000	–	–	1.29%	20
2018 Q1	$6.67M	Buy	+325,000	New	+$8.37M	0.71%	23
2017 Q4	–	Sell	-200,000	Closed	-$6.22M	–	30
2017 Q3	$6.22M	Buy	+200,000	New	+$6.01M	1.42%	16

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Boxer Capital's RETA Position: Q3 2023 in Review

Boxer Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,430,004 shares — an estimated $146M sold.

Boxer Capital first reported a position in RETA in Q3 2017 and held it in 11 quarters. The position peaked at $146M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Boxer Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Boxer Capital sold 1,430,004 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $146M.
Boxer Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 11 quarters.
Boxer Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $146M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.